---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-256326"
form_type: "8-K"
ticker: "TMDX"
cik: "0001756262"
company_name: "TransMedics Group, Inc."
filed_at: "2025-10-29T23:59:59+00:00"
generated_at: "2026-05-17T01:41:33.292909+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TransMedics Q3 revenue $143.8M (+32% YoY); raises FY2025 guidance to $595-605M

## Summary
- Revenue $143.8M, up 32% vs Q3 2024; net income $24.3M ($0.66 diluted EPS) vs $4.2M a year ago.
- Gross margin improved to 59% from 56%; cash balance $466.2M as of Sept 30.
- FY2025 revenue guidance raised to $595-605M (midpoint $600M, 36% growth); prior range was $585-605M.
- Announced strategic collaboration with Mercedes-Benz to deploy V-Class vehicles for organ transport in Italy.
- Owned 21 aircraft as of Sept 30 (22 as of Oct 29); OCS growth driven by NOP and aviation fleet expansion.

## SEC filing metadata
- accession: 0001193125-25-256326
- form_type: 8-K
- ticker: TMDX
- cik: 0001756262
- company_name: TransMedics Group, Inc.
- filed_at: 2025-10-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1756262/000119312525256326/0001193125-25-256326-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1756262/000119312525256326/tmdx-20251029.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-256326
- JSON: https://secwatch.observer/filing/0001193125-25-256326.json
- Plain text: https://secwatch.observer/filing/0001193125-25-256326.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.